1 (587) 885 3158

Welcome to M.A.G.I.C. Clinic LTD!

M.A.G.I.C. stands for Metabolics And Genetics In Calgary 

We focus on caring for children and adults with rare diseases caused by changes in their genes.  There are more than 2,000 known diseases that lead to either metabolic diseases or genetic syndromes. Often, the problems can include neurologic diseases with features like seizures, developmental and growth problems, or heart, liver or muscle diseases where someone’s health continues to get worse and no explanation can be found through standard testing through your doctor.

Examples of METABOLIC DISEASES include things like mitochondrial diseases, leukodystrophies, glycogen storage diseases, fatty acid oxidation defects, lysosomal storage diseases and certain metabolic bone diseases. Examples of GENETIC SYNDROMES include things like Fragile X syndrome, Angelman syndrome, Rett syndrome and many other such conditions.

We use innovative approaches to help find a diagnosis faster and our approach to treatment uses knowledge to improve health but we also deal with specialized medicines to treat rare diseases as well as many research studies.

Location: 1640 – 16th Avenue NW, Suite 304, Calgary, Alberta, Canada

Call: +1 (587) 885-3158

Fax: +1 (866) 566-7683

Email: clinic@calgarymetabolics.hush.com

 

RESEARCH STUDIES

Zamplo is an App that lets you monitor your symptoms, response to therapy, keep track of your medications, make notes and keep track of your medical records all from your smartphone.  It’s free and signing up to the study will open full functionality of the App as part of our research trial.

Helping you stay engaged in your healthcare

Click here to learn more!

WHO WE ARE

New Research Studies
AVRO-RD-02-LTF01

A FOLLOW-UP STUDY OF SUBJECTS WITH TYPE 1 GAUCHER DISEASE WHO PREVIOUSLY RECEIVED AVR-RD-02 GENE THERAPY.

Status: Approved

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

REN001-201

A DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 24 WEEKS TREATMENT WITH REN001 IN PATIENTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM)

status: site selected, ethics application being prepared
ACTIVE RESEARCH STUDIES: CONTACT US IF YOU ARE INTERESTED IN ENROLLING

Gene Therapy Trials:

AVRD-RD-01-201: Gene Therapy for Fabry disease – RECRUITING.

AVRD-RD-02-201: Gene Therapy for Gaucher disease – RECRUITING

301OTC02: OTC Gene Therapy Long Term Follow Up Study – RECRUITMENT COMPLETED

FACTS: Phase 1 Gene Therapy for Fabry disease – RECRUITMENT COMPLETED

Molecular Therapies:

MODIFY Open Label Extension – Open to only those patients that completed the main MODIFY study

SHP 609-203: Intrathecal Elaprase in patients with Hunter syndrome – RECRUITMENT COMPLETED.

EFC13738 / ELIKIDS: Eliglustat in Children with type I Gaucher disease – RECRUITING

ATB200-04: An Open-Label study of Pharmocokinetics, Safety, Efficacy and Pharmacodynamics of ATB200/AT2221 in Pediatrics Subjects Aged 12 to < 18 years with Late-Onset Pompe Disease – RECRUITING

ATB200-07 OLE: Late Onset Pompe disease – RECRUITMENT COMPLETED

Gene Sequencing Studies:

EXOME SCREENING FOR CAUSES OF HYPERTROPHIC CARDIOMYOPATHY LIKE FABRY DISEASE – RECRUITING

Registry and Natural History Studies:

CFDI-NR (Canadian Fabry Disease Initiative Registry) – RECRUITING

FABRY REGISTRY – RECRUITING

GAUCHER DISEASE REGISTRY – RECRUITING

MPS1 REGISTRY – RECRUITING

POMPE DISEASE REGISTRY – RECRUITING

GRIT Study

Dietary Patterns and Supplement Use in Mitochondrial Disease – RECRUITING

Fabry Biomarker Switch ERT STUDY

Oudit Fabry Biomarker Study